Teva Pharmaceutical Industries Ltd ADR Stock
A loss of -1.520% shows a downward development for Teva Pharmaceutical Industries Ltd ADR.
Teva Pharmaceutical Industries Ltd ADR is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
At the moment Teva Pharmaceutical Industries Ltd ADR has reached the predicted target price of 13 €, with a current price of 13.0 €.
For the coming years our community has positive and negative things to say abot the Teva Pharmaceutical Industries Ltd ADR stock. Criterium "Management" gathered the most positive votes but regarding "Conscious of the environment" there were negative voices in the community.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd ADR | -1.520% | 8.197% | 0.763% | 66.667% | 41.631% | 48.481% | -1.859% |
| Bayer AG ADR | -5.710% | 0.000% | -5.036% | -54.795% | -23.256% | -50.376% | -54.795% |
| Roche Holding AG ADR | -0.670% | -1.964% | -5.489% | -20.318% | -13.589% | -17.416% | - |
| GSK plc ADR | 2.560% | 0.000% | -4.020% | 16.463% | 13.690% | -2.051% | -15.170% |
Comments
Teva Pharmaceutical Industries Limited (NYSE: TEVA) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $19.00 price target on the stock, up previously from $12.00.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $15.00 to $17.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $14.00 to $15.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat